Sugi Predict

Sugi Predict / Compounds / SCHEMBL941502

SCHEMBL941502

SCHEMBL941502

CS(=O)(=O)N1CCC(Oc2ccc(Cl)cn2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FPR2 P25090 8/20 0.64
▸ PROKR1 Q8TCW9 8/20 0.64
▸ MMP1 P03956 1/20 0.59
▸ TDO2 P48775 1/20 0.53
▸ CACNB4 O00305 3/20 0.50
▸ CACNA1A O00555 3/20 0.50
▸ CACNA1G O43497 3/20 0.50
▸ CACNG3 O60359 3/20 0.50
▸ CACNA1F O60840 3/20 0.50
▸ CACNA1H O95180 3/20 0.50
▸ CACNB3 P54284 3/20 0.50
▸ CACNA2D1 P54289 3/20 0.50
▸ CACNG7 P62955 3/20 0.50
▸ CACNA1B Q00975 3/20 0.50
▸ CACNA1D Q01668 3/20 0.50
▸ CACNB1 Q02641 3/20 0.50
▸ CACNG1 Q06432 3/20 0.50
▸ CACNB2 Q08289 3/20 0.50
▸ CACNA1S Q13698 3/20 0.50
▸ CACNA1C Q13936 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31688823 0.85 TDO2 (0.54) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL14076021 0.83 FPR2 (0.57) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL15771860 0.83 TDO2 (0.55) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL940600 0.82 MMP1 (0.57) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL17339936 0.81 FPR2 (0.57) FPR2PROKR1MMP1TDO2
SCHEMBL14075865 0.81 FPR2 (0.51) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL7018853 0.80 MMP1 (0.56) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL943749 0.80 MMP1 (0.56) FPR2PROKR1MMP1TDO2CACNB4
SCHEMBL20069052 0.79 HRH3 (0.56) FPR2PROKR1MMP1
SCHEMBL30843204 0.79 FPR2 (0.49) FPR2PROKR1MMP1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 — — US disclosed
US-7625934-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2009-12-01 — — US disclosed
US-7625934-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2009-12-01 — — US disclosed
US-7625934-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2009-12-01 — — US disclosed
US-20080306065-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-12-11 — — US disclosed
US-20040171641-A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2004-09-02 — — US disclosed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 — — US disclosed
US-20040127528-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-01 — — US disclosed
US-6734184-B1 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2004-05-11 — — US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 — — EP disclosed
EP-1370556-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 — — EP disclosed
WO-2002074767-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 — — WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 — — WO disclosed
EP-1109787-A1 ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) AstraZeneca AB (SE) 2001-06-27 — — EP disclosed
WO-2000012478-A1 ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) ASTRAZENECA AB (SE) 2000-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003853-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 FPR2 737/4885PROKR1 2373/4885MMP1 10/4885
US-20040171641-A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) MMP13, MMP25, MMP3 FPR2 1040/4885PROKR1 1779/4885MMP1 11/4885
US-20080306065-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 FPR2 737/4885PROKR1 2373/4885MMP1 10/4885
US-20040127528-A1 Metalloproteinase inhibitors MMP9, MMP10, MMP3 FPR2 1510/4885PROKR1 2106/4885MMP1 17/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 FPR2 1887/4885PROKR1 2512/4885MMP1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.